Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF

NCT07347925 | Recruiting

• 1 other identifier: REC-FPFUE-NO3/2025
• Study Type: observational
• Target: 140
• Locations: 1 country
• Sites: 1

Brief Summary

This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before hospital admission affects short-term health outcomes. The study will compare two groups of participants: those who were already taking ARNI before coming to the hospital and those who were not. Information will be collected from medical records during the hospital stay, including heart-related events, kidney-related events, and how long participants stay in the hospital. Some participants will also be followed for a short period after discharge. This study may help improve understanding of outcomes associated with ARNI use in people with heart failure in routine clinical care.

Conditions

Heart Failure

Keywords

Heart Failure; NYHA class; Sacubitril/Valsartan; Chronic kidney disease

Outcome Measures

Primary Outcomes (1)

• In-hospital cardiac and renal events

  3 months

Secondary Outcomes (1)

• NYHA classification

  3 months

Study Arms (2)

Prehospital ARNI users

Other: Prehospital ARNI use

Non-Prehospital ARNI users

Other: No prehospital ARNI use

Interventions

No prehospital ARNI use OTHER

Participants who were not using ARNI therapy before hospital admission

Non-Prehospital ARNI users

Prehospital ARNI use OTHER

Participants who were using ARNI therapy before hospital admission

Prehospital ARNI users

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adult patients with heart failure and reduced ejection fraction who are admitted to the cardiology wards at Mansoura University Hospital (MUH) during the study period. Participants include those who were already receiving ARNI therapy prior to hospital admission and those who were not, representing typical patients seen in clinical practice.

You may qualify if:

• \>= 18 years, male or female EF \<40%

You may not qualify if:

• EF\>40% Pregnancy or breastfeeding

Sponsors & Collaborators

• Future University in Egypt: lead

Study Sites (1)

Mansoura university Hospital

Al Mansurah, Egypt

RECRUITING

MeSH Terms

Conditions

Heart Failure; Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MS Student, Clinical Pharmacy Department, Future University in Egypt

Study Record Dates

• First Submitted: December 15, 2025
• First Posted: January 16, 2026
• Study Start: January 10, 2026
• Primary Completion: April 15, 2026
• Study Completion: May 1, 2026
• Last Updated: January 16, 2026

Record last verified: 2026-01

Locations

EG (1)